These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 3756388

  • 1. A comparison of the tumour concentrations obtainable with misonidazole and Ro 03-8799.
    Dische S, Saunders MI, Bennett MH, Dunphy EP, Des Rochers C, Stratford MR, Minchinton AI, Wardman P.
    Br J Radiol; 1986 Sep; 59(705):911-7. PubMed ID: 3756388
    [Abstract] [Full Text] [Related]

  • 2. Concentrations achieved in human tumors after administration of misonidazole, SR-2508 and Ro 03-8799.
    Dische S, Saunders MI, Dunphy EP, Bennett MH, Des Rochers C, Stratford MR, Minchinton AI, Orchard RA.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1109-11. PubMed ID: 2943708
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The radiosensitizing effect of metronidazole and misonidazole (Ro-07-0582) on a human malignant melanoma grown in the athymic mutant nude mouse.
    Rofstad EK, Brustad T.
    Br J Radiol; 1978 May; 51(605):381-6. PubMed ID: 638410
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix: an interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix.
    Radiother Oncol; 1993 Feb; 26(2):93-103. PubMed ID: 8465022
    [Abstract] [Full Text] [Related]

  • 10. [Clinical evaluation of hypoxic cell sensitizer (Misonidazole)].
    Asakawa H, Watarai J, Hoshino T.
    Gan To Kagaku Ryoho; 1984 Jun; 11(6):1225-30. PubMed ID: 6732250
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours.
    Brown JM, Yu NY, Workman P.
    Br J Cancer; 1979 Mar; 39(3):310-20. PubMed ID: 465300
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole.
    White RA, Workman P, Brown JM.
    Radiat Res; 1980 Dec; 84(3):542-61. PubMed ID: 6450431
    [No Abstract] [Full Text] [Related]

  • 15. The pharmacokinetics of a new radiosensitiser, Ro 03-8799 in humans.
    Allen JG, Dische S, Lenox-Smith I, Malcolm SL, Saunders MI.
    Eur J Clin Pharmacol; 1984 Dec; 27(4):483-9. PubMed ID: 6519157
    [Abstract] [Full Text] [Related]

  • 16. Desmethylmisonidazole (Ro 05-9963): clinical pharmacokinetics after multiple oral administration.
    Stratford MR, Minchinton AI, Dische S, Saunders MI, Anderson P.
    Int J Radiat Oncol Biol Phys; 1982 Dec; 8(3-4):377-9. PubMed ID: 7107355
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The labelling of EMT-6 tumours in BALB/C mice with 14C-misonidazole.
    Garrecht BM, Chapman JD.
    Br J Radiol; 1983 Oct; 56(670):745-53. PubMed ID: 6616139
    [Abstract] [Full Text] [Related]

  • 19. [Effect of even or uneven dose fractionation regime on murine squamous cell carcinoma with combined use of misonidazole].
    Yasunaga T, Takada C, Takahashi M, Okada S, Sakamoto K.
    Nihon Igaku Hoshasen Gakkai Zasshi; 1983 Oct 25; 43(10):1224-31. PubMed ID: 6672751
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.